|
rs1050171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In exon 20, a variant from CAG to CAA at codon 787 (2361G-> A) was identified in 19 patients, which was a genomic variation of EGFR since it was found in both cancer tissue and white blood cells.
|
22252115 |
2012 |
|
rs1057519847
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
|
rs1057519847
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
|
rs1057519847
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
|
rs1057519848
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
|
rs1057519848
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
|
rs1057519848
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
|
rs1057519861
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression <i>in vitro</i> and <i>in vivo</i><b>Conclusions:</b> Modulation of MEK/ERK-dependent Bim and Mcl-1 degradation critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291.<i>Clin Cancer Res; 23(21); 6567-79.©2017 AACR</i>.
|
28765329 |
2017 |
|
rs1057519861
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Noteworthy effect of slight variation in aliphatic chain length of trisubstituted imidazole inhibitors against epidermal growth factor receptor L858R/T790M/C797S mutant in cancer therapy.
|
30582282 |
2019 |
|
rs1057519861
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We also demonstrated that PE2988 cells, a C797S-independent osimertinib-resistant primary cancer cell line from a lung cancer patient, responded to combined AXL inhibitor and osimertinib treatment.
|
31162839 |
2019 |
|
rs121434568
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
|
rs121434568
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
|
rs121434568
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In two patients, the ctDNA dynamics suggested the presence of cancer cell populations only with the T790M mutation.
|
26678713 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The molecular beacon-based approach enabled rapid and sensitive detection of the EGFR mutation (T790M) in NSCLC with in situ fluorescence imaging, which can be directed to determine various treatment options in patients with cancer.
|
20805561 |
2010 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.
|
30015588 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines.
|
31706682 |
2020 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This approach detects mutations as subtle as the drug-resistance-conferring cancer mutation EGFR T790M (a single C → T substitution) with an estimated specificity of 99.99999%, surpassing even the leading PCR-based methods and enabling detection of 1 mutant molecule in a background of at least 1 million wild-type molecules.
|
30125495 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While they produce dramatic responses in a subset of patients-primarily those with activating EGFR mutations-remissions are typically limited to several months due to acquired drug resistance, frequently associated with the secondary T790M mutation in EGFR.In this issue of Cancer Cell, Li et al. report that an irreversible EGFR kinase inhibitor, HKI-272, had limited activity in a mouse lung cancer model driven by an EGFR mutant harboring T790M and an activating mutation.
|
17613432 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To assess the biological implications of <i>RET</i> fusions in an <i>EGFR</i>-mutant cancer, we expressed CCDC6-RET in PC9 (<i>EGFR</i> del19) and MGH134 (<i>EGFR</i> L858R/T790M) cells and found that CCDC6-RET was sufficient to confer resistance to EGFR tyrosine kinase inhibitors (TKI).
|
30257958 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib.
|
29183267 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M mutations disappeared from cancer cells in the pleural effusion after a break from the treatment drug and cytotoxic agent administration.
|
30145590 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Following drug resistance in patients with lung cancer treated by EGFR TKIs, a biopsy is required to obtain sufficient cancer tissue for T790M detection in order to select potential beneficiaries suitable for third-generation EGFR TKIs, such as osimertinib.
|
31407509 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Indeed, the use of plasma testing to screen for epidermal growth factor receptor (<i>EGFR</i>) T790M mutant positive non-small cell lung cancer (NSCLC) patients eligible for treatment with third-generation EGFR inhibitors was recently approved by the U.S. Food and Drug Administration and is incorporated into the most recent version of the National Comprehensive Cancer Center guidelines as an alternative to tissue biopsy.
|
29184671 |
2017 |